Featuring

Professor John McMurray, Professor of Cardiology (Cardiology & Metabolic Health), School of Cardiovascular and Metabolic Health
Professor Richard Hobbs, Mercian Professor of Primary Care, University of Oxford

References

1. Piccirillo F, Liporace P, Nusca A et al. Effects of finerenone on cardiovascular and chronic kidney diseases: a new weapon against cardiorenal morbidity and mortality‑a comprehensive review. J Cardiovasc Dev Dis 2023;10:236.
2. Kolkhof P, Jaisser F, Kim S-Y et al. Steroidal and novel non‑steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. In Bauersachs J et al (eds): Heart failure. Springer International Publishing, Cham, Switzerland, 2017:271–305.
3. Spironolactone Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/12015/smpc#gref.
4. Eplerenone Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/8810/smpc.

Watch a full-length on-demand video and explore other educational materials, designed to further your understanding of avoiding treatment limbo and alternative approaches to managing dyslipidaemia.

Click here to access prescribing information and adverse event reporting information for Praluent® (alirocumab).